Skip to main content

Table 1 Comparison baseline and follow-up hormone parameters of all patients

From: Graves ophthalmopathy a neglected comorbidity of graves’ disease; a detailed investigation and management of sixty-eight patients in a tertiary healthcare center

N = 68

Baseline

Follow-up

p

TSH (0.38–5.33, mIU/L)

0.07 ± 1.2

3.4 ± 1.9

< 0.001

fT3 (2.3–4.2,pg/mL)

10.5 ± 7.4(3.2–32)

3.6 ± 1.35

< 0.001

fT4 (0.61–1.12,ng/dL)

2.7 ± 2.0 (0.6–11.9)

0.9 ± 0.4

< 0.001

TRAbs (1-1.5, U/L)

12.1 ± 14.3 (0.17-50)

2.3 ± 4.5

< 0.001

AntiTPO (U/mL)

208.7 ± 320.6 (0-1100)

NA

NA

ALT (U/L)

29.6 ± 16.6

21.6 ± 11.8

< 0.001

WBC (103/µL)

7229 ± 1977

7911 ± 2064

0.03

CAS (Score)

0.5 ± 0.8

0.1 ± 0.4

< 0.001

  1. Data is demonstrated as mean standard deviation
  2. CAS: Clinical Activity Score, TSH: Thyroid Stimulating Hormone, fT3: Free T3, fT4: Free T4 WBC: White Blood Cell counter